Expert consensus on clinical application of 177Lu-prostate specific membrane antigen radio-ligand therapy in prostate cancer
- VernacularTitle:177Lu-前列腺特异性膜抗原放射性配体疗法治疗前列腺癌临床应用专家共识
- Author:
Guobing LIU
1
,
2
;
Weihai ZHUO
3
;
Yushen GU
1
,
2
;
Zhi YANG
4
;
Yue CHEN
5
;
Wei FAN
6
;
Jianming GUO
1
,
2
;
Jian TAN
7
;
Xiaohua ZHU
8
;
Li HUO
9
;
Xiaoli LAN
10
;
Biao LI
11
;
Weibing MIAO
12
;
Shaoli SONG
13
;
Hao XU
14
;
Rong TIAN
15
;
Quanyong LUO
16
;
Feng WANG
17
;
Xuemei WANG
18
;
Aimin YANG
19
;
Dong DAI
20
;
Zhiyong DENG
21
;
Jinhua ZHAO
22
;
Xiaoliang CHEN
23
;
Yan FAN
24
;
Zairong GAO
10
;
Xingmin HAN
25
;
Ningyi JIANG
26
;
Anren KUANG
15
;
Yansong LIN
9
;
Fugeng LIU
27
;
Cen LOU
28
;
Xinhui SU
29
;
Lijun TANG
30
;
Hui WANG
31
;
Xinlu WANG
32
;
Fuzhou YANG
33
;
Hui YANG
34
;
Xinming ZHAO
35
;
Bo YANG
36
;
Xiaodong HUANG
37
;
Jiliang CHEN
38
;
Sijin LI
39
;
Jing WANG
40
;
Yaming LI
41
;
Hongcheng SHI
1
,
2
Author Information
- Publication Type:Standardandguideline
- Keywords: 177Lu-prostate specific membrane antigen; prostate cancer; radio-ligand therapy; expert consensus
- From: Chinese Journal of Clinical Medicine 2024;31(5):844-850
- CountryChina
- Language:Chinese
- Abstract: 177Lu- prostate specific membrane antigen (PSMA) radio-ligand therapy has been approved abroad for advanced prostate cancer and has been in several clinical trials in China. Based on domestic clinical practice and experimental data and referred to international experience and viewpoints, the expert group forms a consensus on the clinical application of 177Lu-PSMA radio-ligand therapy in prostate cancer to guide clinical practice.